Advertisement
Screener

OCUGEN, INC. (OCGN) Share-based Payment Arrangement, Noncash Expense

2.8 / 5 stars · 68/120 Roast Me

OCUGEN, INC. Share-based Payment Arrangement, Noncash Expense

OCUGEN, INC. (OCGN) reported Share-based Payment Arrangement, Noncash Expense of $144.00 thousand for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-09.

Discontinued › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2019-08-09

  • OCUGEN, INC. share-based payment arrangement, noncash expense for the quarter ending 2019-06-30 was $37.00K, a 90.91% decline year-over-year.
  • OCUGEN, INC. share-based payment arrangement, noncash expense for the quarter ending 2019-03-31 was $107.00K, a 73.45% decline year-over-year.
  • OCUGEN, INC. share-based payment arrangement, noncash expense for the quarter ending 2018-12-31 was $376.00K, a 10.59% increase year-over-year.
  • OCUGEN, INC. share-based payment arrangement, noncash expense for the quarter ending 2018-09-30 was $439.00K, a 18.97% increase year-over-year.
  • OCUGEN, INC. share-based payment arrangement, noncash expense for fiscal 2018 was $1.63M, a 3.31% increase from fiscal 2017.
  • OCUGEN, INC. share-based payment arrangement, noncash expense for fiscal 2017 was $1.57M, a 1.61% increase from fiscal 2016.
  • OCUGEN, INC. share-based payment arrangement, noncash expense for fiscal 2016 was $1.55M, a 26.06% increase from fiscal 2015.
  • OCUGEN, INC. share-based payment arrangement, noncash expense for fiscal 2015 was $1.23M, a 124.50% increase from fiscal 2014.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2019-06-30$37.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$144.00K
10-Q · filed 2019-08-09
$520.00K
derived: sum of 3 quarters · filed 2019-08-09
$959.00K
derived: sum of 4 quarters · filed 2019-08-09
2019-03-31$107.00K
10-Q · filed 2019-05-15
$483.00K
derived: sum of 2 quarters · filed 2019-05-15
$922.00K
derived: sum of 3 quarters · filed 2019-05-15
$1.33M
derived: sum of 4 quarters · filed 2019-08-09
2018-12-31$376.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22
$815.00K
derived: sum of 2 quarters · filed 2019-03-22
$1.22M
derived: sum of 3 quarters · filed 2019-08-09
$1.63M
10-K · filed 2019-03-22
2018-09-30$439.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$846.00K
derived: sum of 2 quarters · filed 2019-08-09
$1.25M
10-Q · filed 2018-11-08
$1.59M
derived: sum of 4 quarters · filed 2019-08-09
2018-06-30$407.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$810.00K
10-Q · filed 2019-08-09
$1.15M
derived: sum of 3 quarters · filed 2019-08-09
$1.52M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$403.00K
10-Q · filed 2019-05-15
$743.00K
derived: sum of 2 quarters · filed 2019-05-15
$1.11M
derived: sum of 3 quarters · filed 2019-05-15
$1.48M
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31$340.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22
$709.00K
derived: sum of 2 quarters · filed 2019-03-22
$1.08M
derived: sum of 3 quarters · filed 2019-03-22
$1.57M
10-K · filed 2019-03-22
2017-09-30$369.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$741.00K
derived: sum of 2 quarters · filed 2018-11-08
$1.23M
10-Q · filed 2018-11-08
$1.70M
derived: sum of 4 quarters · filed 2018-11-08
2017-06-30$372.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$864.00K
10-Q · filed 2018-08-09
$1.33M
derived: sum of 3 quarters · filed 2018-08-09
$1.76M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$492.00K
10-Q · filed 2018-05-10
$960.00K
derived: sum of 2 quarters · filed 2018-05-10
$1.39M
derived: sum of 3 quarters · filed 2018-05-10
$1.73M
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31$468.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
$901.00K
derived: sum of 2 quarters · filed 2018-03-15
$1.24M
derived: sum of 3 quarters · filed 2018-03-15
$1.55M
10-K · filed 2018-03-15
2016-09-30$433.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
$769.00K
derived: sum of 2 quarters · filed 2017-11-09
$1.08M
10-Q · filed 2017-11-09
$1.45M
derived: sum of 4 quarters · filed 2017-11-09
2016-06-30$336.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10
$647.00K
10-Q · filed 2017-08-10
$1.02M
derived: sum of 3 quarters · filed 2017-08-10
$1.38M
derived: sum of 4 quarters · filed 2017-08-10
2016-03-31$311.00K
10-Q · filed 2017-05-11
$685.00K
derived: sum of 2 quarters · filed 2017-05-11
$1.05M
derived: sum of 3 quarters · filed 2017-05-11
$1.30M
derived: sum of 4 quarters · filed 2017-05-11
2015-12-31$374.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
$736.00K
derived: sum of 2 quarters · filed 2017-03-16
$993.00K
derived: sum of 3 quarters · filed 2017-03-16
$1.23M
10-K · filed 2017-03-16
2015-09-30$362.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10
$619.00K
derived: sum of 2 quarters · filed 2016-11-10
$854.00K
10-Q · filed 2016-11-10
$1.04M
derived: sum of 4 quarters · filed 2016-11-10
2015-06-30$257.00K
10-Q · filed 2015-08-12
$492.00K
10-Q · filed 2016-08-11
$683.00K
derived: sum of 3 quarters · filed 2016-05-12
$851.00K
derived: sum of 4 quarters · filed 2016-05-12
2015-03-31$235.00K
10-Q · filed 2016-05-12
$426.00K
derived: sum of 2 quarters · filed 2016-05-12
$594.00K
derived: sum of 3 quarters · filed 2016-05-12
$706.00K
derived: sum of 4 quarters · filed 2016-05-12
2014-12-31$191.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10
$359.00K
derived: sum of 2 quarters · filed 2016-03-10
$471.00K
derived: sum of 3 quarters · filed 2016-03-10
$547.00K
10-K · filed 2016-03-10
2014-09-30$168.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12
$280.00K
derived: sum of 2 quarters · filed 2015-11-12
$356.00K
10-Q · filed 2015-11-12
2014-06-30$112.00K
10-Q · filed 2015-08-12
$188.00K
10-Q · filed 2015-08-12
2014-03-31$76.00K
10-Q · filed 2015-05-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
AGENUS INC (AGEN)United States$0.383B1.41
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Surrozen, Inc./DE (SRZN)United States$0.395B